We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Type of COVID-19 Test Offers Advantages over Lateral Flow Tests

By LabMedica International staff writers
Posted on 14 Apr 2022
Print article
Image: Nanoparticles could enable a more sensitive rapid COVID-19 test (Photo courtesy of Newcastle University)
Image: Nanoparticles could enable a more sensitive rapid COVID-19 test (Photo courtesy of Newcastle University)

Rapid antigen tests can quickly and conveniently tell a person that they are positive for Covid-19. However, because the antibody-based tests aren’t very sensitive, they can fail to detect early infections with low viral loads. Now, a team of researchers has developed a rapid test that relies on molecularly imprinted polymer nanoparticles, rather than antibodies, for detection.

The gold standard for COVID-19 diagnosis remains the reverse transcription-polymerase chain reaction (RT-PCR). Although this test is highly sensitive and specific, it takes 1-2 days to get a result, is expensive and requires special lab equipment and trained personnel. In contrast, rapid antigen tests are fast (15-30 minutes), and people can take them at home with no training, but they lack sensitivity, sometimes resulting in false negatives. Also, the tests use antibodies against SARS-CoV-2 for detection, which can’t withstand wide ranges of temperature and pH. The research team at Newcastle University (Newcastle, Tyne and Wear, UK) wanted to make a low-cost, rapid, robust and highly sensitive COVID-19 test that uses molecularly imprinted polymer nanoparticles (nanoMIPs) instead of antibodies.

To make nanoMIPs, the researchers began by attaching a peptide from the SARS-CoV-2 spike protein to a solid support. Then, they added nanoparticle building blocks and polymerized them around the peptide, creating nanoparticles with a binding site specific for the coronavirus spike protein. They isolated the nanoparticles that bound most strongly to the peptide and attached them to a screen-printed electrode. After showing that the nanoMIPs could bind SARS-CoV-2, they added the electrode to a small 3D-printed device that measured changes in thermal resistance that occurred upon binding.

When the team added samples from seven patient nasopharyngeal swabs to the device, the liquid flowed over the electrode, and the researchers detected a change in thermal resistance for samples that had previously tested positive for COVID-19 by RT-PCR. The test required only 15 minutes, and preliminary results indicated that it could detect a 6,000-times lower amount of SARS-CoV-2 than a commercial rapid antigen test. Unlike antibodies, the nanoMIPs withstood warm temperatures - which could give the test a longer shelf life in hot climates - and acidic pH - which might make it useful for monitoring SARS-CoV-2 in wastewater. However, to prove that the test has a lower false negative rate than existing rapid antigen tests, it must be tested on many more patient samples, according to the researchers.

“We develop a new type of COVID-19 test which has many advantages over current lateral flow tests. For example, lateral flow tests use biological antibodies to trap and detect the Covid-19 virus, whereas we use a synthetic alternative known as polymer antibodies. This allows for a test which is as fast - 15 mins, and cheap as a lateral flow test but can detect 6000-times smaller amounts of the COVID-19 virus,” said Dr. Marloes Peeters, Senior Lecturer at Newcastle University’s School of Engineering. “Consequently, this will improve test accuracy, particularly for asymptomatic or pre-symptomatic individuals. Moreover, synthetic antibodies are very robust which means the tests have a longer shelf-life, can be used in hot climates with no issues and will not produce false-positive results in acidic media, such as soft drinks.”

“In the future, we hope to further validate our polymer antibody by testing more patient samples, including saliva samples and samples from the omicron variant. Additionally, the polymer antibodies can be easily adapted for any new COVID-19 variants or other emerging pathogens,” added Dr. Peeters.

Related Links:
Newcastle University 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Saliva Collection Kit
SpeciMAX Stabilized Saliva Collection Kit
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx
Microplate Incubator Shaker
iShak TS4 NXT

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.